Skip to main content

Table 3 Comparison of metabolic changes by period and combination antiretroviral therapy regimen in the DGPLEAD study

From: Cardiometabolic risk factors among HIV patients on antiretroviral therapy

  AZT+3TC+NVP (n = 58) D4T+3TC+NVP (n = 43) Other (n = 17) Global P**
Variable Baseline End P* Baseline End P* Baseline End P*  
HDL-c, mmol/L 0.80 [0.61, 1.15] 1.42 [1.17, 1.73] < 0.001 0.65 [0.34, 0.92] 1.27 [1.02, 1.70] < 0.001 0.76 [0.57, 1.03] 1.22 [0.96, 1.47] 0.003 0.22
LDL-c, mmol/L 2.24 [1.76, 2.52] 2.25 [2.00, 2.75] 0.51 2.01 [1.44, 2.42] 2.27 [1.81, 2.61] 0.007 2.06 [1.71, 2.58] 2.14 [1.84, 2.18] 0.41 0.13
TC, mmol/L 3.59 [3.23, 3.99] 4.00 [3.50, 4.68] < 0.001 3.46 [2.85, 4.08] 4.13 [3.59, 4.58] < 0.001 3.40 [2.86, 3.87] 3.50 [3.40, 3.73] 0.77 0.04
TC:HDL-c ratio 4.54 [3.44, 5.84] 2.78 [2.34, 3.49] < 0.001 5.32 [3.97, 8.93] 3.08 [2.85, 3.94] < 0.001 4.34 [3.33, 5.82] 2.73 [2.31, 3.00] 0.001 0.36
TG, mmol/L 1.01 [0.86, 1.33] 1.06 [0.70, 1.41] 0.93 1.16 [1.88, 1.60] 1.05 [0.85, 1.44] 0.41 0.95 [0.77, 1.05] 0.91 [0.68, 1.14] 0.17 0.33
Insulin, μU/mL 3.00 [2.00, 5.00] 6.70 [4.00, 12.50] < 0.001 3.00 [1.50, 5.00] 7.65 [3.00, 13.45] < 0.001 2.60 [1.20, 5.90] 4.65 [3.15, 9.70] 0.07 0.18
Glucose, mmol/L 3.90 [3.60, 4.30] 4.20 [3.60, 4.60] 0.37 3.70 [3.40, 4.10] 3.80 [3.20, 4.60] 0.23 3.60 [3.00, 3.90] 3.70 [3.50, 4.20] 0.17 0.79
HOMA-IR 0.53 [0.33, 0.93] 1.12 [0.62, 2.41] < 0.001 0.50 [0.28, 1.00] 1.39 [0.49, 2.49] < 0.001 0.45 [0.16, 0.98] 0.72 [0.49, 1.53] 0.08 0.07
BMI, kg/m2 20.1 [18.2, 21.5] 20.3 [19.1, 22.2] 0.001 19.6 [18.4, 21.1] 20.6 [19.2, 22.4] < 0.001 19.4 [17.6, 22.4] 20.1 [18.6, 22.3] 0.49 0.26
Weight, kg 55.3 [51.0, 62.0] 58.0 [53.5, 64.0] 0.001 52.0 [46.0, 55.0] 56.0 [47.0, 59.0] < 0.001 53.0 [49.0, 60.5] 55.0 [50.0, 57.0] 0.49 0.30
  1. Values are reported as median [25th percentile, 75th percentile].
  2. * P-values obtained through Wilcoxon signed rank tests.
  3. ** P-values are from ANOVA with robust variance estimators comparing changes from baseline to 90 days after initiating cART and are adjusted for sex.
  4. DGPLEAD, Diet, Genetic Polymorphisms in Lipid-Metabolizing Enzyme genes, and Antiretroviral Therapy-Related Dyslipidemia.